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ABSTRACT 
Chemo-resistant and tumor recurrence are the major hurdle to overcome the cancer patients. Especially in hepatocellular carcinoma 
(HCC) is notoriously refractory to chemotherapy because of its tendency to develop multi-drug resistance (MDR), through various 
mechanisms. Aim: The current research is focussed on understanding the mechanism involved in chemo-resistant and tumor 
recurrence in liver cancer. Methods: Human hepatocellular carcinoma cell line (Huh7) was used entire study. Huh7 cells were 
cultured with known chemotherapeutic drugs such as 5-FU, Paclitaxel and Cisplatin-based on their Cmax concentration, and then 
these drug-treated cells were examined for chemoresistant and tumor recurrence properties through flow cytometry analysis, 
spheroid formation assay, and morphological analysis. Results: In morphological analysis confirm these all the chemo drugs were 
shown more cytotoxic effete than control, even though there were few viable cells noticed in cisplatin treatment. In flow cytometry 
analysis cisplatin pre-treated cells were well expressed LCSC marker such as CD133 and stem cell transduction factors like Oct-4 & 
Nanog than control. In addition to this, all the CD133 expressed cells also expressed to EpCAM. In spheroid formation assay, 
cisplatin pre-treated cells shown well-defined spheroid than control. Conclusion: LCSC plays a major role in chemoresistant and 
tumor recurrence through PI3K/Akt/mTOR, wnt-β catenin signaling, NF-kB signaling. So, targeting LCSC through EpCAM targeted 
therapy along with chemotherapy might be the better option for enhanced prognosis. 
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INTRODUCTION  
Hepatocellular carcinoma (HCC) is one of the most 
common malignancies in the world. Major etiologic 
factors for HCC are chronic viral infections such as 
hepatitis B & C, factors like chronic alcoholism and 
metabolic disorders also modestly involved in HCC 
1
. 
Localized hepatocellular carcinoma patients have an 
excellent survival rate with standard treatment options 
like surgery, chemotherapy, and radiotherapy 
2
. 
However in advance and metastatic disease are 
associated with poor prognosis, and the patients will 
suffer from chemo-resistant and tumor relapse because 
of numerous reason 
3
.  
Chemoresistance is a complex mechanism, involving 
various biological pathways.  Abundant studies have 
reported that multi-drug resistant is associated with over-
expression of ATP binding cassette drug efflux 
4
, DNA 
damage repair 
5-7
, the hypoxia-inducible factor1-α  
(Hif1-α ) 8, epithelial-mesenchymal transition (EMT) 
9,10
, Calcium signalling 
11
,   autophagy induction 
12
, 
epigenetic regulation 
13
, Cancer stem cell 
14
, miRNAs 
15
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and immunosuppressive microenvironment 
16
, have also 
been concerned in that multi-drug resistant. 
Tumour relapse is believed to be a major hurdle for 
cancer treatment. Tumor relapse or cancer recurrence 
arises from incomplete eradication of tumor cells after 
the standard treatment such as surgery, chemotherapy, 
and radiotherapy. There are three important factors 
believed for tumor relapse such as cancer stem cells 
(CSCs), neosis, and a phoenix rising 
17
. 
Since the new concept of cancer stem cells (CSCs) was 
introduced in the late 1990s, it has gradually gained 
worldwide acceptance and influenced all approaches to 
cancer research and therapy. The CSC, which are also 
accurately called ‘tumor-initiating cells', represent a 
small population of cancer cells, sharing common 
properties with normal stem cells (SCs), that can initiate 
new tumors following injection into animal models, 
while the majority of other cancer cells cannot 
18
. The 
reported fractions of CSCs in tumors vary from 0.1 to 
30% depending on the type and the advancement of 
cancer 
19
. 
Signaling pathway such as PI3K/Akt/mTOR, wnt-β 
catenin signaling, NF-kB signaling, Hotch signaling are 
actively involving in cancer stem cell activation. 
Especially the activation of wnt-β catenin signaling 
pathway has been observed 1/3 in Hepatocellular 
carcinoma.  wnt-β catenin signaling pathway plays a 
major role in tumor initiation, activation, invasion and 
metastasis in hepatocellular carcinoma 
20
. 
This current study was designed to understand the 
mechanism involved in chemo-resistance and tumor 
recurrence using well known chemotherapeutic drugs 
such as cisplatin, 5flurouracil, and paclitaxel treatment. 
MATERIALS AND METHODS 
Reagents:  
Cisplatin (Cat#1550), and Paclitaxel (cat #1567), 
purchased from Bio vision, and 5-fluorouracil (cat 
#F6627) purchased from Sigma.  HepG2 cell lines were 
purchased through National Centre for Cell Science 
(NCCS), Pune. Fetal bovine serum (Cat#11573397) 
purchased from Gibco. Antibiotic-Antimycotic 
(cat#15240062) purchased from Gibco. ITS 
(Cat#41400045) purchased from Invitrogen. FITC-
conjugated CD133 monoclonal antibody (clone # 
EMK08, Cat# 11-1339-41) was purchased from 
eBioscience. PE-conjugated EpCAM monoclonal 
antibody (clone # EBA-1, Cat# 347198), PE-conjugated 
Nanog monoclonal antibody (clone # N31-355, Cat# 
561300), FITC-conjugated Oct-4 monoclonal antibody 
(clone # 40/oct-3, Cat# 560253) was purchased from BD 
Bioscience. 
Cell culture /Drug sensitivity assay  
Huh7 cells were obtained from NCCS, Pune. The cells 
were cultured in complete RPMI 1640 medium 
supplemented with 10% FBS, ITS, antibacterial and anti 
antifungal up to 3 passages to get enough cells, then 
these cells were seeded in 6 well plates, incubated at 
least for 24 hours, once reached above 80% confluence, 
these cells were treated with half the value of Cmax 
concentration  of Cisplatin (1.655 µg/ml ), 5-FU (8.3 
µg/ml ),  and Paclitaxel (1.595 µg/ml) for 3 days at 37oC 
in 5% CO2 Incubator. Drug medium was changed at 
every alternative day. The image was captured under the 
inverted microscope.  
Flow cytometry  
The pre-treated Huh7 cells were dissociated with 0.25 % 
trypsin-EDTA (1 mM) (Invitrogen) for 3 min and 
washed with Calcium and magnesium-free Dulbecco 
phosphate buffered saline solution by spinning at 300g 
for 7 minutes 4 °C. Then these cells were diluted in 100 
µl FACS buffer (PBS containing 1 % fetal bovine 
serum) and then incubated for 1 h at 4 °C in FACS 
buffer with the corresponding mAb: anti-CD133- FITC 
and anti-EpCAM-PE. After incubation washes the cells 
by spinning at 300g for 7 minutes at 4°C, discard the 
supernatant and add 200 µl of FACS buffer for analysis. 
Flow cytometry analysis was performed with a BD 
FACSCanto II flow cytometer (BD Biosciences). 
Huh7 cells and Pre drug-treated Huh7 cells were 
dissociated with 0.25 % trypsin-EDTA (1 mM) 
(Invitrogen) for 3 min and washed with Calcium and 
magnesium-free Dulbecco phosphate buffered saline 
solution by spinning at 300g for 7 minutes 4 °C. Then 
these cells were fixed and permeabilized by BD 
Transcription factor buffer (Fix/perm) for 30 minutes at 
4°C. Then wash the cells by spinning at 300g for 7 
minutes at4 °C. Discard the supernatant and add 100 µl 
of BD Transcription factor buffer (perm/wash) to the 
cells and then incubated for 45 minutes at 4 °C with the 
corresponding mAb: anti-oct-4 FITC and anti-Nanog-
PE. After incubation washes the cells by spinning at 
300g for 7 minutes at 4°C, discard the supernatant and 
add 200 µl of FACS buffer for analysis. Flow cytometry 
analysis was performed with a BD FACSCanto II flow 
cytometer (BD Biosciences). 
Spheroid formation assay  
3D cell culture reagent, Matrigel (Cat.no: 354230) was 
obtained from BD Biosciences and was used to culture 
liver spheroids. 5 mg/ ml concentration of matrigel was 
prepared and used for culturing spheroids. HepG2 cells 
were treated with low dose cisplatin, paclitaxel, 5-FU for 
3 days respectively. Then these cells were harvested and 
1000 Cells/96 well plate were incubated at 37 °C 
degrees with 5 % CO2 and culture to get the optimal 
spheroid size. Culture medium was refreshed every 2-
3days up to 9 days. 
RESULTS 
Morphological analysis 
The morphology of control cells remains the same after 
cultured 3 days also, whereas in drug-treated cells were 
shrinking and lost their morphology.  The cell death was 
observed equally in every concentration of drug-treated 
cells and also there is no much difference shown in 
cisplatin, 5-FU, paclitaxel-treated cells. It's clearly 
evident that these drugs have shown their cytotoxic 
effects in maximum levels and whatever leftover viable 
cells were capable of resisting the chemotherapy. 
Sekar et al                                                                                                          Journal of Drug Delivery & Therapeutics. 2018; 8(5):224-229           
ISSN: 2250-1177                                                                             [226]                                                                             CODEN (USA): JDDTAO 
 
Figure 1: Microscopic examination of drug-treated Huh7 cells. Paclitaxel, 5-FU & cisplatin treated cells shows 
increased cell death when compared to control cells. 
Screening of conventional chemotherapy which 
promotes more cancer stem cells in liver cancer? 
Part of low dose chemo drugs treated cells were stained 
for cancer stem cell marker CD133 and analyzed in flow 
cytometry. CD133, a well-studied cancer stem cell 
marker expression was highly enriched at 5.6% in low 
dose cisplatin-treated cells and subsequently, the 
expression pattern was decreased in low dose paclitaxel 
3.45% and low dose 5-FU 1.98%. Even though low dose 
paclitaxel and low dose5-fu treated cells were 
significant expresses the CSC marker it's not as good as 
low dose cisplatin treated cell expression. It means all 
the three drugs were promoting cancer stem cells but 
only low dose cisplatin drug is capable for far above the 
ground level of chemoresistant and cancer relapse than 
other two drugs. In clonogenic assay draw a parallel 
result of the flow cytometry.  In cisplatin pretreated cell 
were able to form decent colonies, but paclitaxel and 5-
FU pre-treated cells were unable to form as well as 
cisplatin pre-treated.  
 
 
 
Figure 2: Flow cytometry analysis, LCSC expression was enriched in cisplatin-pretreated cells and followed by 5-FU 
and paclitaxel pretreated cells. 
Analysis of the tumor recurrence properties using 
spheroid formation assay 
Tumor recurrence or Tumor relapse is a major obstacle 
in cancer therapy. We evaluate the tumor recurrence 
properties in ex vivo by using spheroid formation assay. 
5-FU, Paclitaxel, Cisplatin pre-treated Huh7 cells along 
with control Huh7 cells were subjected to spheroid 
formation assay. Interestingly we observed distinct 
spheroids in Cisplatin pre-treated cells and undersized 
spheroids in 5-FU and Paclitaxel pre-treated cells. There 
was no spheroid observed in control Huh7 cells even 
after 9 days of culture. These findings confirm that 
LCSC plays the major role in tumor relapse. 
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Figure 3: Spheroid formation assay experiment shows well-defined spheroid formation in cisplatin pre-treated cells 
when compared to other drug-treated cells. 
Transduction Factors as CSC Markers involved in 
liver cancer Chemo-resistance 
Stem cell transcription factors like Octamer 4 (Oct4), 
Nanog expression levels were dramatically increased in 
chemoresistant cancer cells due to DNA demethylation 
regulation of Oct4 and Nanog. Flow cytometry analysis, 
we observed the enhanced expression of Oct4 and 
Nanog in Huh7 cell line whereas in normal liver cell line 
expression was very low. It is well evident that the Oct4-
TCL1-AKT pathway and Nanog pathway acts on 
embryonic stem cells and cancer stem cells in cell 
proliferation through inhibition of apoptosis. 
 
Graph 1: The stem cell transduction factors marker such 
as Oct-4 & Nanog expressions are drastically increased 
in cisplatin pre-treated cells than control. 
CSC associated signaling pathway in liver cancer 
Chemo-resistance  
Notch, wnt-β-catenin, PI3/AKT & NF-kB pathways are 
mainly involved in liver cancer stem cells but most 
researchers studied EpCAM wnt-βcatenin pathway to 
understanding cancer stem cell and chemoresistant of 
various cancer. The EpCAM signaling pathway can be 
activated by intramembrane proteolysis and shedding of 
the extracellular domain of EpCAM. EpCAM was 
sequentially cleaved by two important proteins named as 
tumor necrosis factor-alpha converting enzyme (TACE) 
and presenilin 2(PS-2) as EpEX and EpICD. EpEX is 
released out of the cell, whereas EpICD is released into 
the cytoplasm. Four and one-half LIM domain protein 2 
(FHL2) is a protein which contains two binding sites 
such as EpCAM and β-Catenin. FHL2 is identified as a 
cytosolic interaction partner for EpICD, and also it 
regulates the TACE and PS-2 protein activities. 
Simultaneously the Wnt signaling pathway activated by 
the binding of Wnt ligand with its receptor such as 
frizzled and LRP 5/6, recruits disheveled and induce β-
Catenin degradation complex (AXIN, APC, GSK3). 
This complex inhibits the phosphorylation of β-Catenin. 
Therefore the β-Catenin gets accumulated in the 
cytoplasm. This accumulated β-Catenin binds with 
FHL2 and EpICD complex and translocates into the 
nucleus. The large nuclear complex proteins regulate 
gene transcription and activate the EpCAM target genes 
such as c-myc cyclins, and TCF1. So, targeting wnt-
βcatenin signaling may help in an inhibition of cancer 
stem cells in liver cancer. 
EpCAM positive cells are the key regulators of LCSC 
and chemo-resistant 
In the morphological examination, we noticed even after 
5 days of cisplatin treatment the Huh7 cells were not 
undergone cell death completely. It's so, part of the 
cancer tissue have the potential to resist the chemo 
drugs. To further confirm this correlation between 
chemoresistant and cancer stem cells, these cells were 
studied the cancer stem cell markers such as EpCAM 
and CD133 using flow cytometry. FACS analysis results 
indicate that a majority of EpCAM+ cells express 
CD133 in HuH7 cells, which prompted us to compare 
the tumorigenic capacity of EpCAM+ and CD133+ cells 
in these cell lines. Noticeably, EpCAM+ HuH7 cells 
showed marked tumor-initiating capacity compared with 
CD133+ HuH7 cells, whereas EpCAM+ and CD133+ 
cells had the similar tumorigenic ability in HuH7 cells. 
This data confirms the direct association between CSCs 
and chemoresistant and further convince that EpCAM is 
one of the important key markers in regulating CSCs. 
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Figure 4: Schematic representation of EpCAM signaling pathway: Intracellular domain of EpCAM (EpICD) cleaved by TACE and 
PS-2 enzymes and translocate into the cytoplasm. Meanwhile, ß- Catenin accumulates in the cytoplasm due to the inhibition of ß- 
Catenin degradation complex (AXIN, GSK3 ß, APC) in Wnt - ß Catenin pathway. With help of FHL2, EpICD and ß Catenin enters 
into the nucleus. These nuclear complex proteins regulate gene transcription and activate the EpCAM target gene such as Cyclins 
and C-myc. 
 
Figure 5: Flow cytometry analysis of LCSC marker CD133 & 
EpCAM. 
DISCUSSION AND CONCLUSION 
Yi Chen et al 2012 reported that CD133+EpCAM+ cells 
have capable of initiating tumour cells in Huh7 cells 
compared with CD133+EpCAM-, CD133-EpCAM+, 
CD133-EpCAM- cells, including enrichment in side 
population cells, higher differentiation capacity, 
increased colony-formation ability, preferential 
expression of stem cell-related genes, appearance of 
drug-resistant to some chemotherapeutics, more 
spheroid formation of culture cells and stronger 
tumorigenicity in NOD/SCID mice 
21
 Taro Yamashita et 
al 2009 confirmed that EpCAM+ AFP+ HCC cells are 
shown hepatic stem/progenitor cells features and these 
cells were capable of initiating highly invasive HCC in 
NOD/SCID mice. Also they found that aberrant Wnt/β-
catenin signalling activation in EpCAM positive cells 
than EpCAM negative cells and blockage of EpCAM 
resulted in decrease Wnt/β-catenin signalling activation 
22
. Gedaly R et al claim that arresting the Wnt/b-catenin 
pathway could inhibit the LCSC activation in HCC, and 
this was correlated with a decrease cells proliferation in 
S phase 
20
. Chemoresistance and tumor recurrence is a 
major hurdle in therapeutics in many cancers including 
liver cancer. Our findings confirm that Cisplatin chemo 
drugs unable to kill Huh7 cells completely. Further 
analysis of this resistance cells, we observed liver cancer 
stem cell marker like CD133 expression was elevated in 
cisplatin-pretreated cells. Interestingly CD133 positive 
cells also express EpCAM. These results were 
reconfirmed by analyzing stem cells transduction factors 
such as Oct4 and Nanog in Cisplatin pretreated cells and 
control. Interestingly Oct4 and Nanog expression was 
increased in cisplatin pre-treated cells than control. 
Cisplatin pre-treated cells were able to form well distinct 
spheroids than other chemo drug pretreated cells, and no 
spheroid formation in control even after 9 days of 
culture. This finding suggests that tumor recurrence 
propertied in ex vivo. Based on all the results it's 
confirming that cancer stem cell plays a major role in 
chemoresistant and tumor recurrence so, targeting liver 
CSC through EpCAM targeted therapy might be a better 
choice to an enhanced prognosis of hepatocellular 
carcinoma.  
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